Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled clinical study of an anti-PD-1 checkpoint inhibitor with adjunctive microbiome therapy (SER-401) in patients with advanced metastatic melanoma

Trial Profile

A randomized, placebo-controlled clinical study of an anti-PD-1 checkpoint inhibitor with adjunctive microbiome therapy (SER-401) in patients with advanced metastatic melanoma

Planning
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs SER-401 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Aug 2018 According to a Seres Therapeutics media release, company is advancing work with collabarator at MD Anderson Cancer Center and the Parker Institute for Immunotherapy to begin a Phase 1b study.
    • 02 Aug 2018 According to a Seres Therapeutics media release,study expected in patients with metastatic melanoma treated with checkpoint inhibitors by year end .
    • 21 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top